Evidence-based study on postoperative chemotherapy guidelines/consensuses for ovarian epithelial tumor

LUO Xiandan; LU Yanli; WU Yihang; GUO Yanxiang; YAN Xiaoyi; HUO Yongchao; YAN Hui; YANG Zhenjiang; ZHANG Hongliang

doi:10.6039/j.issn.1001-0408.2025.18.20

您当前的位置：

首页 >

文章列表页 >

Evidence-based study on postoperative chemotherapy guidelines/consensuses for ovarian epithelial tumor

更新时间：2025-09-25

- Evidence-based study on postoperative chemotherapy guidelines/consensuses for ovarian epithelial tumor
- ZHONGGUO YAOFANG Vol. 36, Issue 18, Pages: 2328-2333(2025)
- 作者机构：
  
  广西医科大学第一附属医院药学部，南宁　530021
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.18.20
  CLC： R979.1
- Received：01 April 2025，
  
  Revised：2025-08-26，
  
  Accepted：27 August 2025，
  
  Published：30 September 2025
- 稿件说明：
移动端阅览
罗鲜丹,陆艳丽,吴亦航,等.卵巢上皮癌术后化疗指南/共识的循证研究[J].中国药房,2025,36(18):2328-2333.

LUO Xiandan,LU Yanli,WU Yihang,et al.Evidence-based study on postoperative chemotherapy guidelines/consensuses for ovarian epithelial tumor[J].ZHONGGUO YAOFANG,2025,36(18):2328-2333.
罗鲜丹,陆艳丽,吴亦航,等.卵巢上皮癌术后化疗指南/共识的循证研究[J].中国药房,2025,36(18):2328-2333. DOI： 10.6039/j.issn.1001-0408.2025.18.20.

LUO Xiandan,LU Yanli,WU Yihang,et al.Evidence-based study on postoperative chemotherapy guidelines/consensuses for ovarian epithelial tumor[J].ZHONGGUO YAOFANG,2025,36(18):2328-2333. DOI： 10.6039/j.issn.1001-0408.2025.18.20.

摘要

目的

系统评价卵巢上皮癌术后化疗指南/共识的方法学质量。

方法

检索PubMed、Embase、Web of Science、中国生物医学文献数据库、维普网、中华医学期刊全文数据库、万方数据和中国知网，以及GIN、NICE、医脉通、AHRQ、CSCO、ASCO、NCCN等官网，检索时限为建库/建站至2025年3月10日。使用临床指南研究与评价系统Ⅱ（AGREE-Ⅱ）对纳入指南/共识的质量进行评价。

结果

共纳入指南/共识16篇。AGREE-Ⅱ评价的各领域得分分别为：范围和目的85.07%、参与人员47.92%、严谨性57.49%、清晰性88.02%、应用性8.20%和独立性53.39%。其中，14篇的推荐等级为B级，2篇为C级。按不同国家/地区、不同研究类型的亚组分析结果显示，我国指南/共识的参与人员、严谨性、独立性得分均显著低于国外（

＜0.05）；指南的参与人员、严谨性得分均显著高于共识（

＜0.05）。指南/共识推荐意见结果显示，B级指南/共识推荐铂类药物为基础的联合化疗为Ⅰ期高级别浆液性癌患者的首选辅助化疗方案；推荐铂类药物为基础的联合化疗±贝伐珠单抗为Ⅱ～Ⅳ期高级别浆液性癌患者辅助化疗以及铂敏感复发性高级别浆液性癌患者化疗的首选方案；推荐非铂类药物单药±贝伐珠单抗为铂耐药复发性高级别浆液性癌患者化疗的首选方案。

结论

卵巢上皮癌术后化疗的指南/共识总体质量不高；我国指南/共识的方法学质量相较于国外尚有差距，推荐意见与国外存在差异。建议完善参与人员、严谨性和独立性领域，根据卵巢癌的不同分期特点推荐治疗方案，制定符合我国国情的指南/共识。

Abstract

OBJECTIVE

To systematically evaluate the methodological quality of the postoperative chemotherapy guidelines/consensuses for ovarian epithelial tumor.

METHODS

A search was conducted across databases including PubMed， Embase， Web of Science， CBM， VIP， Chinese Medical Journal Data， Wanfang Data， and CNKI， as well as the official websites of GIN， NICE， Medlive， AHRQ， CSCO， ASCO， and NCCN. The search period was from the establishment of the databases/websites to March 10， 2025. The quality of the included guidelines/consensus was evaluated by using the AGREE-Ⅱ tool.

RESULTS

A total of 16 guidelines/consensuses were included. The domain scores of AGREE-Ⅱ evaluation were as follows： scope and purpose of 85.07%， participants of 47.92%， rigor of development of 57.49%， clarity of presentation of 88.02%， applicability of 8.20%， and independence of 53.39%. Among them， 14 were recommended at grade B and 2 were recommended at grade C. The subgroup analysis by different countries/regions and di

fferent types of studies showed that the scores for participants， rigor of development， and independence of the guidelines/consensuses in China were significantly lower than foreign countries （

＜0.05）； the scores for participants and rigor of development of the guidelines were significantly higher than consensuses （

＜0.05）. The guideline/consensus recommendation results indicated that grade B guidelines/consensus recommend platinum-based combination chemotherapy as the preferred adjuvant chemotherapy regimen for stage Ⅰ high-grade serous carcinoma patients；platinum-based combination chemotherapy±bevacizumab was recommended as the preferred adjuvant chemotherapy regimen for stage Ⅱ-Ⅳ high-grade serous carcinoma patients and for platinum-sensitive recurrent high-grade serous carcinoma patients； non-platinum single-agent chemotherapy±bevacizumab was recommended as the preferred chemotherapy regimen for platinum-resistant recurrent high-grade serous carcinoma patients.

CONCLUSIONS

The overall quality of postoperative chemotherapy guidelines/consensuses for ovarian epithelial tumor is not high. The methodological quality of guidelines/consensuses in China is still lagging behind that of foreign countries. The recommendations differ from those in foreign countries. It is recommended to improve the aspects of participants， rigor of development， and independence， to recommend treatment plans based on the different stages of ovarian cancer， and develop guidelines/consensuses that align with China’s national conditions.

关键词

Keywords

references

BRAY F ， LAVERSANNE M ， SUNG H ， et al . Global cancer statistics 2022：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin ， 2024 ， 74 （ 3 ）： 229 - 263 .

VENEZIANI A C ， GONZALEZ-OCHOA E ， ALQAISI H ， et al . Heterogeneity and treatment landscape of ovarian carcinoma [J ] . Nat Rev Clin Oncol ， 2023 ， 20 （ 12 ）： 820 - 842 .

WANG Z K ， GUO E S ， YANG B ， et al . Trends and age-period-cohort effects on mortality of the three major gynecologic cancers in China from 1990 to 2019：cervical，ovarian and uterine cancer [J ] . Gynecol Oncol ， 2021 ， 163 （ 2 ）： 358 - 363 .

PRAT J . New insights into ovarian cancer pathology [J ] . Ann Oncol ， 2012 ， 23 （ Suppl. 10 ）： x111 - x117 .

方丽萍，李妮，貟海娟，等 . 术后辅助化疗治疗晚期卵巢癌患者的临床疗效 [J ] . 癌症进展， 2023 ， 21 （ 21 ）： 2423 - 2425 .

杨丽，罗太敏，秦先涛，等 . 贝伐珠单抗联合紫杉醇类化疗药物治疗铂耐药复发性卵巢癌的Meta分析 [J ] . 中国临床药学杂志， 2023 ， 32 （ 6 ）： 436 - 443 .

贺哲，张杰，翁雨雄，等 . DRG支付方式改革下大型公立医院临床路径实施策略分析 [J ] . 中国医院管理， 2024 ， 44 （ 4 ）： 70 - 73 .

BROUWERS M C ， KHO M E ， BROWMAN G P ， et al . AGREE Ⅱ：advancing guideline development，reporting and evaluation in health care [J ] . CMAJ ， 2010 ， 182 （ 18 ）： E839 - E842 .

廖少君，詹吉恒，侯宇，等 . 神经根型颈椎病临床实践指南和专家共识方法学与报告质量评价 [J ] . 中国中西医结合杂志， 2024 ， 44 （ 10 ）： 1197 - 1205 .

张福强，胡紫腾，张钰菁，等 . 中成药临床实践指南制定方法（八）：基于AGREE Ⅱ和RIGHT的中成药临床实践指南质量评价 [J ] . 中医杂志， 2024 ， 65 （ 2 ）： 185 - 201 .

关舒予，常天瀛，王健康，等 . 基于AGREE Ⅱ对急性心肌梗死临床指南的质量评价 [J ] . 中国实验方剂学杂志， 2025 ， 31 （ 10 ）： 201 - 209 .

National Comprehensive Cancer Network . NCCN clinical practice guidelines in oncology：ovarian cancer continue including fallopian tube cancer and primary peritoneal cancer：version 1.2025 [EB/OL ] .[ 2025-03-15 ] . https：//guide.medlive.cn/guideline/34514 https://guide.medlive.cn/guideline/34514 .

中国临床肿瘤学会 . 卵巢癌诊疗指南：2024 [EB/OL ] .[ 2025-03-15 ] . https：//meeting.csco.org.cn/pdf/web/viewer.html?file=/Upload/Periodical/20241225021207.pdf https://meeting.csco.org.cn/pdf/web/viewer.html?file=/Upload/Periodical/20241225021207.pdf .

TOKUNAGA H ， MIKAMI M ， NAGASE S ， et al . The 2020 Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer，fallopian tube cancer，and primary peritoneal cancer [J ] . J Gynecol Oncol ， 2021 ， 32 （ 2 ）： e49 .

HIRTE H ， POON R ， YAO X M ， et al . Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage Ⅱ- Ⅳ epithelial ovary，fallopian tube，or primary peritoneal carcinoma：a systematic review [J ] . Curr Oncol ， 2022 ， 29 （ 1 ）： 231 - 242 .

GONZÁLEZ-MARTÍN A ， HARTER P ， LEARY A ， et al . Newly diagnosed and relapsed epithelial ovarian cancer：ESMO clinical practice guideline for diagnosis，treatment and follow-up [J ] . Ann Oncol ， 2023 ， 34 （ 10 ）： 833 - 848 .

MOSS E ， TAYLOR A ， ANDREOU A ， et al . British Gynaecological Cancer Society（BGCS）ovarian，tubal and primary peritoneal cancer guidelines：recommendations for practice update 2024 [J ] . Eur J Obstet Gynecol Reprod Biol ， 2024 ， 300 ： 69 - 123 .

Scottish Intercollegiate Guidelines Network . SIGN 135： management of epithelial ovarian cancer：a national clinical guideline [EB/OL ] .[ 2025-03-15 ] . https：//guide.medlive.cn/guideline/21560 https://guide.medlive.cn/guideline/21560 .

PEREZ-FIDALGO J A ， GÁLVEZ-MONTOSA F ， GUERRA E M ， et al . SEOM-GEICO clinical guideline on epithelial ovarian cancer：2023 [J ] . Clin Transl Oncol ， 2024 ， 26 （ 11 ）： 2758 - 2770 .

Belgian Health Care Knowledge Centre . Ovarian cancer：diagnosis，treatment and follow-up [EB/OL ] .[ 2025-08-02 ] . https：//kce.fgov.be/en/publications/all-reports/ovarian-cancer-diagnosis-treatment-and-follow-up https://kce.fgov.be/en/publications/all-reports/ovarian-cancer-diagnosis-treatment-and-follow-up .

SUH D H ， CHANG S J ， SONG T ， et al . Practice guidelines for management of ovarian cancer in Korea：a Korean Society of Gynecologic Oncology consensus statement [J ] . J Gynecol Oncol ， 2018 ， 29 （ 4 ）： e56 .

蓝春燕，王雅卓，张师前 . 铂敏感复发性卵巢癌诊治中国专家共识：2023年版 [J ] . 中国实用妇科与产科杂志， 2023 ， 39 （ 9 ）： 935 - 942 .

卢淮武，温灏，邹冬玲，等 . 卵巢上皮性癌一线化疗中国专家共识 [J ] . 实用妇产科杂志， 2022 ， 38 （ 8 ）： 582 - 588 .

张德普，孙阳，张师前，等 . 黏液性卵巢癌诊断与治疗中国专家共识：2021年版 [J ] . 中国微创外科杂志， 2021 ， 21 （ 7 ）： 577 - 588 .

刘军秀，陈怡李，高国兰，等 . 老年卵巢癌诊治中国专家共识 [J ] . 现代肿瘤医学， 2024 ， 32 （ 24 ）： 4569 - 4579 .

LEDERMANN J A ， MATIAS-GUIU X ， AMANT F ， et al . ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer：pathology and molecular biology and early，advanced and recurrent disease [J ] . Ann Oncol ， 2024 ， 35 （ 3 ）： 248 - 266 .

蓝春燕，董延磊，张师前，等 . 低级别浆液性卵巢癌诊治中国专家共识：2024年版 [J ] . 中国癌症防治杂志， 2025 ， 17 （ 1 ）： 11 - 20 .

邵丽华，张秋宁，田金徽，等 . 食管癌临床指南和共识的质量评价 [J ] . 中国循证医学杂志， 2020 ， 20 （ 5 ）： 593 - 603 .

胡菲菲，何俊勇，何礼霞，等 . 2014—2018年中国宫颈癌临床实践指南的方法学质量评价 [J ] . 中国循证医学杂志， 2019 ， 19 （ 8 ）： 989 - 993 .

田昕彤，马腾，孙璇，等 . 老年高血压临床指南现状分析及质量评价 [J ] . 中国全科医学， 2022 ， 25 （ 34 ）： 4259 - 4266，4285 .

王吉耀 . 从循证医学观点评估和应用临床指南 [J ] . 中华消化杂志， 2004 ， 24 （ 7 ）： 385 - 386 .

陈耀龙，罗旭飞，王吉耀，等 . 如何区分临床实践指南与专家共识 [J ] . 协和医学杂志， 2019 ， 10 （ 4 ）： 403 - 408 .

MUTCH D G ， PRAT J . 2014 FIGO staging for ovarian，fallopian tube and peritoneal cancer [J ] . Gynecol Oncol ， 2014 ， 133 （ 3 ）： 401 - 404 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Quality evaluation of Chinese and global guidelines/consensus for TDM of anti-TNF-α agents in patients with inflammatory bowel disease

Analysis and evaluation of the application of polymyxin B in inpatients based on clinical guidelines and consensuses

Related Author

ZHU Mengxin

XIE Cheng

XIA Fan

YU Di

LI Yue

XI Qinhua

ZHU Jianguo

JIN Tanghui

Related Institution

Dept. of Pharmacy， the First Affiliated Hospital of Soochow University

Dept. of Gastroenterology， the First Affiliated Hospital of Soochow University

Dept. of Pharmacy， Tianjin Medical University General Hospital

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰